After Eli Lilly announced it would take measures to cap insulin prices on March 1, Novo Nordisk is now following suit. Given what is known about the changes in diabetes management, there may be strategic reasoning behind these moves.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,